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tivecommons.org/licenses/by-nc-Summary Background: Hepatitis C virus (HCV) infection can lead to increased insulin resis-
tance, but the dynamics of insulin resistance in HCV-infected patients receiving pegylated
interferon plus ribavirin remain elusive.
Methods: This prospective study enrolled HCV-infected patients who received pegylated inter-
feron plus ribavirin. Patients were classified according to the attainment of sustained virolog-
ical response (SVR). Insulin resistance was measured using homeostatic model assessment-
insulin resistance (HOMA-IR). The change in HOMA-IR at baseline, the end of treatment, and
24 weeks after the end of treatment was compared in patients who achieved SVR and those
who did not.
Results: A total of 65 patients participated in this study, of which 46 (71%) achieved SVR. Over-
all, The HOMA-IR changed significantly during antiviral therapy, with the median values [inter-
quartile range (IQR)] of 3.7 (1.6e10.0) prior to the treatment, 1.5 (0.8e2.9) at the end, and 1.6
(0.9e3.1) at 24 weeks after completion of therapy. However, only patients who achieved SVR
had significant off-therapy reduction of HOMA-IR, with median values of 1.3 (IQR, 0.7e2.6) at
24 weeks off therapy and 3.6 (IQR, 1.5e9.9) at baseline (p < 0.0001). In those without SVR, the
HOMA-IR measured 24 weeks after treatment completion (median, 2.2; IQR, 1.9e4.7) did not
differ from baseline values (median, 3.9; IQR, 2.2e10.0; p Z 0.5).of Internal Medicine and Center for Database Research, E-Da Hospital/I-Shou University, Number 1,
com (Y.-C. Hsu).
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44 C.-H. Tseng et al.Conclusion: Dual therapy with pegylated interferon plus ribavirin ameliorated IR in HCV-
infected patients, but the off-therapy improvement of IR was limited to those who attained
SVR.
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Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatitis C virus (HCV) infection is causally associated
with impaired glucose homeostasis. Epidemiological sur-
veys have consistently revealed a higher prevalence of
insulin resistance and diabetes mellitus (DM) in HCV-
infected patients than in the general population or in
those with other chronic liver diseases [1e9]. HCV infec-
tion may cause insulin resistance, which is the essential
component of metabolic syndrome and type 2 DM, through
the direct involvement of viral proteins or as an indirect
consequence of infection-related cytokine dysregulation
[8,10e13].
Because chronic HCV infection is causally associated with
impaired glucose homeostasis, it is plausible that viral
clearancemay ameliorate insulin resistance and prevent DM.
Current evidence, however, remains inconclusive in con-
firming the efficacy of successful HCV eradication in
improving glucose intolerance. Several follow-up studies
observing treatedpatients have reported encouraging results
by demonstrating a lower incidence of new-onset type 2 DM
in HCV-infected patients who achieved sustained virological
response (SVR), as compared with those who could not clear
the virus [14e16]. Nevertheless, these studies could not
ascertain whether the apparent reduction of DM incidence
was the result of viral eradication or simply reflected that
patients who were more likely to develop DM were more
difficult to treat. Several studies showed that HCV-infected
patients with insulin resistance were more difficult to treat
[17,18]. In order to elucidate how antiviral treatment as well
as viral clearance may impact the glucose homeostasis in
patients with HCV infection, it is imperative to measure in-
sulin resistance alongside the therapeutic course.
We conducted this study to explore the change in insulin
resistance from the baseline, through the end of, and to 24
weeks after the standard regimen with pegylated inter-
feron plus ribavirin. The association between viral clear-
ance and amelioration of insulin resistance was assessed.Patients and methods
Study design and patient population
This is a prospective cohort study of HCV-infected patients
receiving standard antiviral therapy in a regional teaching
hospital in southern Taiwan (E-Da Hospital, Kaohsiung,
Taiwan). The study protocol was approved by the Institu-
tional Review Board of E-Da Hospital (EMRP-099-112). Pa-
tients were eligible if they were older than 20 years, were
seropositive for HCV antibody, had detectable HCV RNA inserum, and had elevated serum alanine aminotransferase.
Those who met any of the following exclusion criteria were
not enrolled: coinfection with human immunodeficiency
virus or hepatitis B virus, alcohol abuse (daily consumption
converted to more than 40 mL pure ethanol), presence of
other concomitant liver diseases (hemochromatosis, Wilson
disease, drug-related hepatitis, or alpha-1 antitrypsin
deficiency), pregnant or lactating women, severe comor-
bidity (malignancy, major psychiatric disorder, or failure of
vital organ), contraindication for interferon-based therapy,
and lack of informed consent.
Antiviral therapy
All patients were treated with response-guided pegylated
interferon alpha-2b (1.5 mg/kg per week; PEG-Intron;
Schering-Plough Inc., Kenilworth, NJ, USA) and ribavirin
(Rebetol; Schering-Plough Inc., Las Piedras, Puerto Rico)
with dosage adjusted on the basis of body weight (1200 mg/
d for weight  100 kg; 1000 mg/d for weight < 75 kg). Pa-
tients who achieved rapid virological response received a
24-week therapy; those who failed to attain rapid virological
response but could achieve early virological response were
treated for 48 weeks. Undetectable HCV RNA 24 weeks after
the completion of therapy defined the achievement of SVR.
The HCV RNA test was performed at a central laboratory
(Taipei Institute of Pathology, Taipei, Taiwan) for HCV RN
level using second-generation real-time polymerase chain
reaction assay (COBAS AmpliPrep/COBAS TaqMan HCV
Quantitative Test, version 2.0; Roche Molecular Diagnostics,
Branchburg, NJ, USA; detection limit,15 IU/mL) and for HCV
RNA genotype by LINEAR ARRAY Hepatitis C Virus Genotyping
Test (Roche Molecular Diagnostics, Branchburg, NJ, USA).
Methods of measurement and definition of insulin
resistance
Prior to the antiviral therapy, patients were interviewed
and physically examined to obtain comprehensive personal
information. Body mass index (BMI) was calculated as the
patient’s weight in kilograms divided by the square of
height in meters. HCV genotyping was performed according
to Simmonds’ system.
Venous blood for laboratory examinations was collected
in the morning after an overnight fast at baseline, at the
end of the therapy, and 24 weeks after the cession of
therapy. Insulin resistance was measured indirectly with
homeostasis model assessment (HOMA-IR) method using the
following formula:
fasting glucose (mg/dL)  fasting IRI (mU/mL)/405.
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Theoutcomeof interestwas the change inHOMA-IR during the
antiviral therapy. Continuous variables are expressed with
median and interquartile range (IQR) and categorical vari-
ables with percentage of occurrence. For comparison of
continuous variables, the Wilcoxon matched-pairs signed-
ranks test was used for values collected at different time
points in the same patient, and the rank-sum test for
between-group comparison. Fisher’s exact test was used for
analysis of proportions. All statistical analyses were two-
tailed and carried out using a commercial software package
(Stata, version 9.1; Stata Corp., College Station, TX, USA). A p
value < 0.05 was the threshold for statistical significance.Results
Baseline characteristics of the study population
A total of 65 patients were enrolled in this study (Table 1).
This cohort included 41 men (63.1%). The predominant viralTable 1 Baseline characteristics of the study
participants.
Characteristics
Age, y 53 (45e59)
Male sex 41 (63.1)
Body mass index, kg/m2 24.8 (22.7e26.2)
Waist circumference, cm 89.5 (82e96)
Hip circumference, cm 99.3 (94e104.5)
Waist/hip ratio 0.90 (0.86e0.94)
HCV genotype
Genotype 1 36 (55.4)
Genotype 2 27 (41.6)
Genotype 6 1 (1.5)
Mixed genotypes 1 (1.5)
HCV RNA, IU/mL 8.6  105
(5.9  104e3.7  106)
AST, IU/L 93 (69e122)
ALT, IU/L 129 (82e200)
Creatinine, mg/dL 1.1 (0.9e1.2)
Platelet, 103/mL 172 (143e215)
Hemoglobin, g/dL 14.7 (13.8e15.7)
Leukocyte, /mL 6180 (4890e7090)
Diabetes mellitus 12 (18.5)
Hypertension 16 (24.6)
Cirrhosis 5 (7.7)
Glucose, mg/dL 98 (90e120)
Insulin, mU/mL 13.5 (7.3e33.6)
HOMA-IR 3.7 (1.6e10.0)
C peptide, ng/mL 3.3 (2.0e6.1); 4.3  3.1
Cholesterol, mg/dL 182 (158e212)
LDL, mg/dL 100 (79e125)
Triglyceride, mg/dL 152 (103e201)
Triglyceride, mg/dL 152 (103e201)
Data are presented as n (%) or n (range).
ALT Z alanine aminotransferase; AST Z aspartate aminotrans-
ferase; HCVZ hepatitis C virus; HOMA-IR Z homeostatic model
assessment-insulin resistance; LDL Z low-density lipoprotein.genotypes was type 1 (55.4%, nZ 36) and followed by type
2 (41.6%, n Z 27). The median viral load prior to antiviral
therapy was 8.6  105 (IQR, 5.9  104e3.7  106) IU/mL.
The pretreatment median value of HOMA-IR was 3.7 (IQR,
1.6e10.0), and the median concentration of C-peptide was
3.3 (IQR, 2.0e6.1) ng/mL. After antiviral treatment, 71%
(n Z 46) successfully achieved SVR.
Change in HOMA-IR during antiviral therapy and the
association with SVR
Overall, HOMA-IR changed significantly during the antiviral
therapy (Fig. 1), with a median value (IQR) of 3.7
(1.6e10.0) prior to the treatment, 1.5 (0.8e2.9) at the end
of course, and 1.6 (0.9e3.1) 24 weeks after the completion
of treatment (Fig. 1). From baseline to the end of therapy,
HOMA-IR decreased significantly in patients who achieved
SVR and in those who did not (Table 2).
However, only patients who achieved SVR maintained
amelioration of insulin resistance after 24 weeks off the
antiviral regimen (Fig. 2A), whereas those who failed to
achieve viral eradication had HOMR-IR rebound after 24
weeks off treatment (Fig. 2B). The median values of HOMA-
IR in patients with SVR were 1.3 (IQR, 0.7e2.6) and 3.6
(IQR, 1.5e9.9) at 24 weeks after completion of therapy and
at baseline, respectively (p < 0.0001). In those without
SVR, the median HOMA-IR 24 weeks off therapy was 2.2
(IQR, 1.9e4.7), statistically similar with 3.9 (IQR, 2.2e10.0)
prior to treatment (p Z 0.46).
Change in BMI during antiviral therapy and the
association with SVR
The BMI decreased significantly during the antiviral therapy
in both patients who achieved SVR and those who did not,
and increased in both groups (Fig. 3 and Table 3). In pa-
tients who achieved SVR (Fig. 3A and Table 3), BMI at
baseline and that at 24 weeks off therapy did not signifi-
cantly differ (p Z 0.1).Figure 1 Change in HOMA-IR levels during therapy and 24
weeks off therapy in all patients. (HOMA-IR Z homeostatic
model assessment-insulin resistance).
Table 2 Change in HOMA-IR during antiviral treatment among study participants.
Baseline End of therapy pa 24 wk off therapy pa
Overall (n Z 65) 3.7 (1.6e10.0) 1.5 (0.8e2.9) <0.0001 1.6 (0.9e3.1) 0.0001
SVR (n Z 46) 3.6 (1.5e9.9) 1.4 (0.6e2.7) 0.001 1.3 (0.7e2.6) <0.0001
No SVR (n Z 19) 3.9 (2.2e10.0) 2.1 (0.8e4.8) 0.002 2.2 (1.9e4.7) 0.46
HOMA-IR Z homeostatic model assessment-insulin resistance; SVR Z sustained virological response.
a p values calculated by Wilcoxon matched-pairs signed-ranks test, with baseline measurement as the reference for comparison.
Figure 2 Change in HOMA-IR levels during therapy and 24 weeks off therapy in (A) patients with sustained virological response
(SVR) and (B) those without SVR. (HOMA-IR Z homeostatic model assessment-insulin resistance).
Figure 3 Change in body mass index (BMI) during therapy and 24 weeks off therapy in (A) patients with sustained virological
response (SVR) and (B) those without SVR.
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This prospective study unraveled how insulin resistance
would change during the antiviral treatment for HCV
infection. We demonstrated a significant reduction of in-
sulin resistance in infected patients after they finished the
therapy with pegylated interferon plus ribavirin. However,Table 3 Change in BMI during antiviral treatment among study
Baseline End of therap
Overall (n Z 65) 25.1 (23.5e26.3) 23.2 (21.3e25
SVR (n Z 46) 24.4 (22.7e25.8) 22.9 (21.2e24
No SVR (n Z 19) 26.0 (24.6e28.9) 24.3 (22.5e26
BMI Z body mass index; SVR Z sustained virological response.
a p values calculated by Wilcoxon matched-pairs signed-ranks test,off-therapy amelioration of insulin resistance was observed
only in patients who achieved SVR, indicating that viral
clearance is essential for the efficacy to be sustained.
Collectively, these findings corroborate the causative role
of HCV in impairing glucose homeostasis and implicate the
clinical effectiveness of viral eradication in extrahepatic
outcomes.participants.
y pa 24 wk off therapy pa
.1) <0.0001 24.6 (22.7e26.7) 0.01
.8) <0.0001 24.3 (22.6e25.6) 0.1
.6) 0.0001 25.9 (22.7e29.4) 0.03
with baseline measurement as the reference for comparison.
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countries have recently reported the efficacy of anti-HCV
therapy in improving insulin resistance [19e21]. All of these
studies also indicated the importance of successful clear-
ance. For instance, investigators of the HALT-C (Hepatitis C
Antiviral Long-term Treatment against Cirrhosis) trial
showed that HOMA-IR changed in a linear fashion according
to virological response during the antiviral treatment, after
adjusting for the baseline insulin resistance and other po-
tential confounders including BMI, age, sex, and liver
fibrosis [20]. Similar results were reported from the
Virahep-C study, which exclusively enrolled genotype 1-
infected patients with insulin resistance (HOMA-IR >2) at
baseline [19]. Given that relevant data from the East re-
mains relatively sparse [22e25], this study, which was
conducted in an ethnic Chinese population, adds to the
growing body of literature in elucidating the influence of
HCV on mediating glucose and energy balance.
It is intriguing to note that insulin resistance decreased at
the end of the antiviral therapy in most patients regardless of
their virological response. The direct pharmacological activity
of interferon is unlikely to be the reason because available
data indicate that interferon actually induces insulin resis-
tance, instead of ameliorating it [26e28]. The most plausible
explanation for this finding probably relates to the effects on
appetite and body weight during the interferon-based
regimen. Conjeevaram and colleagues [19] reported in a
large cohort that BMI significantly decreased during interferon
therapy irrespective of virological response. They further
pointed out that weight loss was usually transient and main-
tained until completion of the therapy. Accordingly,
improvementof insulin resistancethat results fromweight loss
should also be short-lived. Sustained amelioration of insulin
resistance in patientswho achieved SVR, therefore, cannot be
accounted for by the change in bodyweight. This is consistent
withour study. It also appears rational that remissionof insulin
resistancemay derive from improvement of liver fibrosis after
viral clearance, insomuch as that the stage of fibrosis corre-
lates with the severity of glucose abnormality [6]. Nonethe-
less, regression of liver fibrosis usually takes a long time
and unlikely to occur 6 months off therapy. All in all, these
lines of evidence indicate that HCV per se is the inciting eti-
ology for aberrant glucose homeostasis in infected individuals.
Our findings implicate that antiviral treatment for HCV
infection may decrease clinical complications that patho-
genically result from impaired glucose control. Previous
studies have shown that HCV not only increases the risk of
DM [1e3], but also raises the hazard of relevant clinical
complications such as renal failure and stroke [29,30].
Through amelioration of insulin resistance and subsequent
betterment of glycemic control, viral eradication could
thereby improve renal and cardiovascular outcomes in
diabetic patients. Therefore, this study lends support to a
recent nationwide cohort study that utilized a national
claim database to uncover the association of antiviral
treatment with improved renal and cardiovascular out-
comes in diabetic patients with HCV infection [31].
There are several limitations in our study. First, the
sample size did not suffice for a subgroup analysis. As a
result, we could not further analyze how viral genotype or
viral load might influence the change in insulin resistance.
From the existing literature, HCV-related insulin resistanceis most likely present across different genotypes [4],
although some studies suggest it is more frequent in geno-
types 1 and 4 [6,32]. Further studies are warranted to
elucidate whether change in insulin resistance during
antiviral treatment will differ according to viral genotype.
Second, therapeutic duration was not standardized in our
study cohort because the regimen was guided by virological
response. This limitation apparently has led to variable
dosage of antiviral drugs among participants. However, it
did not affect insulin resistance measured 24 weeks off
treatment because direct pharmacological effects of these
drugs should have already waned completely by then.
In conclusion, antiviral therapy improves insulin resis-
tance during HCV treatment. The durability persists only in
patients who achieve SVR. These findings suggest that HCV
plays an etiological role in the pathogenesis of impaired
glucose homeostasis. Moreover, the reversibility of insulin
resistance through viral eradication implicates tremendous
clinical benefits by readily available regimens.Conflicts of interest
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